Fatty acids for enhancing ketogenic diets
The restriction and resistance of the ketogenic diet is solved by combining the dietary fiber blend of C4 or C6 fatty acids, C2 fatty acids, citric acid and nicotinamide nucleosides in the non-ketogenic ketogenic diet strengthening agent composition, and improved the restriction and resistance of the ketogenic diet. The durability of ketone body production and ketosis state is suitable for epilepsy prevention.
Patent Information
- Application Number
- CN202380036048.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-02
- Filing Date
- 2023-03-01
- Publication Date
- 2024-12-03
AI Technical Summary
The existing ketogenic diet is highly restrictive, has low patient compliance, and can easily lead to increased resistance to ketosis or the frequency of epilepsy, making it difficult to follow and maintain the ketosis status for a long time.
Using a non-ketogenic ketogenic diet enhancer composition, including C4 or C6 fatty acids, C2 fatty acids, citric acid and nicotinamide nucleosides, provides a non-ketogenic amount through a dietary fiber blend to enhance ketosis and prevent ketogenic diets. Resistance, reduce dietary fat demand, improve ketone production and maintain ketosis.
It improves the production and maintenance of ketogenic diet, reduces resistance to the keto diet, reduces the amount of dietary fat required, enhances the durability of the ketosis state, and is suitable for epilepsy prevention in patients with epilepsy.
Smart Images

Figure BDA0005099686480000231 
Figure BDA0005099686480000241 
Figure HDA0005099686490000011
Abstract
Description
Technical Field
[0001] The present invention relates to the use of non-ketogenic ketogenic diet-boosting compositions to produce elevated and sustained levels of ketone bodies in the blood for transitioning to nutritional ketosis or maintaining nutritional ketosis, and to non-ketogenic ketogenic diet-boosting compositions for this purpose. Background Art
[0002] Ketosis is a state of elevated blood ketone levels due to a ketogenic diet, caloric restriction, (therapeutic) fasting, and / or supplementation with ketogenic precursors. Ketone bodies are energy substrates for both peripheral tissues and the central nervous system. The two most abundant and physiologically significant ketone bodies are acetoacetate and β-hydroxybutyrate, while the third ketone body, acetone, is exhaled from the lungs as a byproduct.
[0003] The metabolism of ketone bodies has been implicated in therapeutic effects in a variety of therapeutic areas, including neurological disorders (e.g., epilepsy and aging-related conditions such as Alzheimer's disease), neuromuscular diseases (e.g., amyotrophic lateral sclerosis, stroke, and neurotrauma), metabolic disorders (e.g., obesity, insulin resistance, type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases).
[0004] Among other things, the rise of ketone bodies in the blood has been shown to improve blood sugar control, inhibit inflammation, reduce mitochondrial reactive oxygen species (ROS) production and favorably change mitochondrial bioenergetics. Ketone bodies increase the hydraulic efficiency of the heart, while reducing oxygen consumption, while increasing ATP production. Therefore, the ketone bodies that rise increase metabolic efficiency, and therefore reduce superoxide production and increase reduced glutathione, which then further increases ATP production and metabolic efficiency. From a neurological point of view, one of the mechanisms by which ketone bodies realize their potential is the biochemical process through their energy metabolism. During cellular respiration in mitochondria, glucose enters the citric acid cycle via the glycolytic pathway, which is interrupted or impaired in many brain diseases or trauma situations. Ketone bodies enter the citric acid cycle independently of glycolysis, and are therefore considered to save the energy metabolism of cells.
[0005] It is believed that the ketogenic diet (KD) causes adaptive changes in brain energy metabolism, thereby increasing energy production. This is thought to help neurons remain stable under increased energy demands and may confer neuroprotection. The classic KD, consisting of high fat, low protein, and low carbohydrates, typically with a fat to protein and carbohydrate ratio of up to 4:1, was first introduced in the 1920s for use in human childhood epilepsy. The KD was originally suggested to mimic the metabolic state and biochemical changes associated with fasting, as fasting has been shown to have anticonvulsant properties.
[0006] In subjects receiving KD, fatty acids are used as the main fuel source. These fatty acids are used by fatty acid oxidation in cell mitochondria. During the day, the brain uses glucose as fuel, and lipids in the form of plasma lipoproteins themselves do not cross the blood-brain barrier to a large extent. The liver can use long-chain fatty acids to synthesize three ketone bodies, beta-hydroxybutyrate, acetoacetate, and acetone. These ketone bodies can cross the blood-brain barrier and serve as glucose substitutes during sleep or other fasting periods at night. Due to the non-expression of enzymes in the mitochondrial b-oxidation pathway, brain neurons have a very limited ability to use fatty acids as fuel, and therefore rely on providing ketones as fuel during fasting. When fat and carbohydrates are present in neurons at the same time, glucose will be the preferred energy source by far, while lipids are preferably stored and not used for ketone production. This is why the classic ketogenic diet has a large amount of excess lipids and almost no digestible carbohydrates. Typically, when the amount of digestible carbohydrates in the diet increases, the degree of ketosis is significantly reduced.
[0007] The medium-chain triglyceride ketogenic diet (MCTKD) is a variation of the classic ketogenic diet, with about 30%-70% MCT fat. The idea of MCTKD is that because MCT produces more ketones than regular fats (mainly composed of LCT), incorporating a large amount of MCT into the diet allows patients to maintain ketosis while consuming relatively high amounts of protein and carbohydrates. In the original MCT diet developed in the 1970s, 60% of the calories came from MCT oil. Although consuming such an amount of MCT oil causes abdominal cramps, diarrhea, and vomiting, which is a serious disadvantage of its use, the MCT content of MCTKD is generally limited to about 20% of the total calories of the diet. Like the ketogenic diet, the diet is unpalatable, which makes it difficult to follow. In addition, the health effects of a very high-fat diet on life can be considerable.
[0008] The modified Atkins diet (MAD) is another more liberal variation of the traditional ketogenic diet, which is primarily restricted to the amount of digestible carbohydrates. While ketogenic diets are often given as a 4:1 or 3:1 ketogenic ratio, which is the ratio of the amount of fat to the combined amount of protein and digestible carbohydrates, the MAD involves a ratio of about 1:1, which allows for more protein and carbohydrate intake and requires less fat intake. While the MAD allows for more food choices and is easier to follow than the classic ketogenic diet, it is less ketogenic than the classic ketogenic diet and is therefore not as effective as the classic ketogenic diet.
[0009] A low glycemic index diet is another dietary variation that allows for the induction of ketosis. The glycemic index categorizes carbohydrates according to their potential to raise blood sugar on a scale of 0-100. A low glycemic index diet allows for the intake of more digestible carbohydrates, but the carbohydrates are limited to those with a low glycemic index (generally considered to be 55 or less). In practice, low GI nutrition induces a mild ketogenic state, and patients find the diet easier to follow than a classic ketogenic diet.
[0010] Although the KD is effective in raising blood ketone levels and has potential for widespread application, patient compliance is low due to the restrictive nature of the diet. In addition, despite following the KD, some epilepsy patients develop resistance to ketosis induction or experience an increase in the frequency or severity of epileptic seizures. Moreover, if carbohydrates are consumed in excess of the restricted amount, subjects on the ketogenic diet immediately switch back to glucose utilization, meaning a decrease in ketone production and levels. Accordingly, there remains a need to develop compositions and methods that are not affected by the shortcomings of existing ketogenic diets. Such compositions and methods will be useful for improving compliance of subjects using a ketogenic diet and / or enhancing the ketosis state and / or increasing the production of ketone bodies. Summary of the invention
[0011] The inventors have observed that the level of ketone bodies produced by the ketogenic diet is increased after administration of a non-ketogenic ketogenic diet-boosting agent composition. The inventors have found that at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is beneficial for the following therapeutic uses: (i) enhancing ketosis and / or (ii) preventing and / or treating resistance to a ketogenic diet in a subject following / adopting a ketogenic diet, wherein at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid or a derivative thereof is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is provided in a non-ketogenic amount by a dietary fiber blend contained in a non-ketogenic ketogenic diet-boosting agent composition. Treating resistance to a ketogenic diet includes reducing the severity of resistance to a ketogenic diet.
[0012] In other words, the present invention relates to the use of a non-ketogenic ketogenic diet-boosting composition in the manufacture of a product for (i) enhancing ketosis and / or (ii) preventing and / or treating resistance to a ketogenic diet, wherein at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is contained in the non-ketogenic ketogenic diet-boosting composition, or at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is provided in a non-ketogenic amount by a dietary fiber blend contained in the non-ketogenic ketogenic diet-boosting composition.
[0013] Furthermore, the present invention contemplates a (non-therapeutic) method for (i) enhancing ketosis and / or (ii) preventing / treating resistance in a (healthy) subject in need thereof and following a ketogenic diet, the method comprising administering to the subject at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid, wherein at least one of the C4 or C6 fatty acid and optionally a C2 fatty acid is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least one of the C4 or C6 fatty acid and optionally a C2 fatty acid is provided in a non-ketogenic amount by a fiber blend in the non-ketogenic ketogenic diet-boosting agent composition.
[0014] In particular, the present invention provides non-ketogenic ketogenic diet-boosting agent compositions, methods of use, and uses for increasing ketone production in subjects on a ketogenic diet, maintaining and / or improving ketosis, and / or preventing or treating tolerance to a ketogenic diet in subjects on a ketogenic diet. In specific embodiments, the ketogenic boosting agent composition increases the amount of ketone bodies produced by a ketogenic diet, which means that less dietary fat is needed to maintain a ketotic state in a subject on a ketogenic diet.
[0015] In certain embodiments, the non-ketogenic ketogenic diet-boosting agent composition is for use in preventing seizures in a subject with epilepsy who is on a ketogenic diet.
[0016] The present invention provides a non-ketogenic ketogenic diet-enhancing agent composition, the composition comprising
[0017] (i) at least one of C4 and C6 fatty acids, more preferably at least C4 fatty acids
[0018] (ii) optionally, one or more of C2 fatty acids, citric acid and / or nicotinamide riboside.
[0019] The present invention further relates to a non-ketogenic ketogenic diet-boosting agent composition consisting essentially of:
[0020] (i) 0.2 mg to 1.2 g C4 fatty acids;
[0021] (ii) 5 mg to 17 g of C6 fatty acids;
[0022] (iii) 10 mg to 20 g of citrate; and
[0023] (iv) 0.5 mg to 1.5 g nicotinamide riboside,
[0024] These amounts are based on the dry weight of the composition per serving.
[0025] The present invention further relates to a non-ketogenic ketogenic diet-boosting agent composition consisting essentially of:
[0026] (i) 20 mg to 1.2 g C2 fatty acids;
[0027] (ii) 4 mg to 480 mg C4 fatty acids;
[0028] (iii) 260 mg to 3.3 g C6 fatty acids;
[0029] (iv) 0.2 mg to 4.4 g citrate; and
[0030] (v) 12 mg to 286 mg nicotinamide riboside,
[0031] wherein the weight ratio of C2 and C4 fatty acids:C6 fatty acids is between 1:1.8 and 1:2.1, preferably between 1:1.9 and 1:2.0, based on dry weight;
[0032] The weight ratio of C2 and C4 fatty acids:citrate is between 1:2.4 and 1:2.7, preferably between 1:2.5 and 1:2.6, and
[0033] The weight ratio of C2 and C4 fatty acids: nicotinamide riboside is between 1:0.15 and 1:0.19, preferably between 1:0.16 and 1:0.18, and wherein the total weight of the composition is between about 10-20 grams.
[0034] Figure List
[0035] The present invention will be discussed in more detail below with reference to the accompanying drawings.
[0036] Figure 1: Effects of C2 fatty acids on hepatocyte ketone production.
[0037] Figure 2: Effects of C4 fatty acids on ketone production in hepatocytes.
[0038] Figure 3: Effects of C6 fatty acids on ketone production in hepatocytes.
[0039] Figure 4: Effects of citric acid on hepatocyte ketone production.
[0040] Figure 5: Effects of nicotinamide riboside on ketone production in hepatocytes.
[0041] Figure 6: Effects of nicotinamide riboside on hepatocyte ketone production under ketogenic conditions.
[0042] Figure 7: Effects of combinations of C4 and C6 fatty acids on hepatocyte ketone production.
[0043] Figure 8 : Effects of combinations of C4, C6, citrate, and NR or NAM on hepatocyte ketone production.
[0044] Fig. 9: Weight ratio of butyrate to propionate from 24-h fermentation of dietary fiber.
[0045] List of Examples
[0046] 1. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use in the treatment of:
[0047] (i) enhance ketosis associated with a ketogenic diet and / or
[0048] (ii) preventing and / or treating resistance to a ketogenic diet,
[0049] Wherein at least one of C4 or C6 fatty acids and optionally C2 fatty acids is contained in the non-ketogenic ketogenic diet-boosting agent composition, or at least C4 or C6 fatty acids and optionally C2 fatty acids are provided in non-ketogenic amounts by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the non-ketogenic ketogenic diet-boosting agent composition.
[0050] 2. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to embodiment 1, wherein enhancing ketosis means increasing the blood ketone concentration in a subject on a ketogenic diet using a non-ketogenic ketogenic diet-boosting composition compared to the blood ketone concentration in a subject consuming the same ketogenic diet without the use of a non-ketogenic ketogenic diet-boosting composition.
[0051] 3. At least one of the C4 or C6 fatty acids and optionally C2 fatty acids for use according to embodiments 1 and 2, wherein the non-ketogenic ketogenic diet-boosting agent composition further comprises one or more compounds selected from the group consisting of a) citric acid and / or b) nicotinamide riboside and / or nicotinamide.
[0052] 4. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding embodiments, wherein the non-ketogenic ketogenic diet-boosting agent composition is in the form of a nutritional supplement.
[0053] 5. at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding embodiments,
[0054] wherein the at least C4 or C6 fatty acid and optionally the C2 fatty acid are provided in a non-ketogenic amount by a butyrate dietary fiber or a butyrate dietary fiber blend, and
[0055] Wherein these dietary fibers are selected from pectin, glue, gum, galacto-oligosaccharide, oligofructose, inulin, polyfructose, oligofructose, arabinogalactan, hemicellulose, resistant starch, fuji soybean, oligosaccharide, or a mixture thereof, and
[0056] Wherein these dietary fibers have a fermentation profile providing butyrate and propionate in a weight ratio of at least 1, preferably at least 1.1.
[0057] 6. A C4 or C6 fatty acid and optionally at least one of its C2 fatty acids for use according to any of the preceding embodiments, wherein the amount of the C4 fatty acid is 0.2 mg to 12 mg per kg body weight per day, and / or the amount of the C6 fatty acid is 5 mg to 185 mg per kg body weight per day.
[0058] 7. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding embodiments, wherein the non-ketogenic ketogenic diet-boosting composition is administered one to six times per day, preferably three to four times per day, or continuously, or wherein the non-ketogenic ketogenic diet-boosting composition is administered continuously by tube.
[0059] 8. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any one of the preceding embodiments, wherein the subject following a ketogenic diet suffers from a condition selected from the group consisting of:
[0060] i) Neurological diseases, including epilepsy, stroke, traumatic brain injury, and migraine;
[0061] ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and age-related mild cognitive impairment (MCI);
[0062] iii) neuromuscular disease, including amyotrophic lateral sclerosis, muscle deactivation, muscle atrophy and sarcopenia caused by aging, or risk of or frailty in old age;
[0063] iv) psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder;
[0064] v) metabolic disorders, including insulin resistance, type 1 and type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases;
[0065] vi) tumor diseases;
[0066] vii) Cardiovascular disease leading to heart failure.
[0067] 9. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any one of the preceding embodiments, wherein the subject following a ketogenic diet is a subject suffering from epilepsy.
[0068] 10. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any one of the preceding embodiments, wherein maximal levels of ketosis are increased.
[0069] 11. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding embodiments, wherein the non-ketogenic ketogenic diet-boosting agent composition comprises
[0070] (i) C4 fatty acids
[0071] (ii) C6 fatty acids
[0072] (iii) citric acid, and
[0073] (iv) nicotinamide riboside or nicotinamide, and optionally
[0074] (v) C2 fatty acids.
[0075] 12. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding embodiments, wherein the non-ketogenic ketogenic diet-boosting composition is administered at a dose of:
[0076] (i) 0.2mg to 12mg C4 fatty acids per kg body weight per day
[0077] (ii) 6.5mg to 163mg C6 fatty acids per kg body weight per day
[0078] (iii) 0.011 g to 0.39 g citric acid per kg body weight per day, and
[0079] (iv) 0.6 mg to 14.3 mg nicotinamide riboside or an equivalent range of nicotinamide per kg body weight per day, and optionally (v) 0.5 mg to 30 mg C2 fatty acids per kg body weight per day.
[0080] 13. A non-therapeutic method for treating healthy subjects following a ketogenic diet
[0081] (i) Enhance ketosis and / or
[0082] (ii) Preventing resistance to the ketogenic diet
[0083] The method comprises administering to the subject at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid, wherein one of the C4 or C6 fatty acid and optionally a C2 fatty acid is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least the C2 or C4 fatty acid or a derivative thereof is provided in a non-ketogenic amount by a butyrate dietary fiber blend in the non-ketogenic ketogenic diet-boosting agent composition.
[0084] 14. The non-therapeutic method of embodiment 13, wherein the method is used to promote non-therapeutic weight loss and / or improve recovery after exercise, and wherein optionally, promoting non-therapeutic weight loss is carried out in subjects with a BMI between 18 and 25, preferably between 20 and 25.
[0085] 15. A non-ketogenic ketogenic diet-boosting agent composition consisting essentially of:
[0086] (i) 0.2 mg to 1.2 g C4 fatty acids;
[0087] (ii) 5 mg to 17 g of C6 fatty acids;
[0088] (iii) 10 mg to 20 g of citrate; and
[0089] (iv) 0.5 mg to 1.5 g nicotinamide riboside or nicotinamide, wherein these amounts are based on the dry weight of the composition, and wherein these amounts are on a per serving basis, and wherein optionally the composition is in the form of a supplement.
[0090] 16. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use in the treatment of:
[0091] (i) enhance ketosis associated with fasting or intermittent fasting,
[0092] wherein at least one of the C4 or C6 fatty acids and optionally the C2 fatty acids is contained in the non-ketogenic ketogenic diet-boosting agent composition, or at least one of the C4 or C6 fatty acids and optionally the C2 fatty acids is provided in a non-ketogenic amount by a butyrate dietary fiber blend contained in the non-ketogenic ketogenic diet-boosting agent composition. DETAILED DESCRIPTION
[0093] The present invention provides non-ketogenic ketogenic diet-boosting agent compositions, methods of use, and uses for increasing ketone production in a subject on a ketogenic diet, maintaining and / or improving ketosis, and / or preventing or treating tolerance to a ketogenic diet in a subject on a ketogenic diet.
[0094] It has been found that at least one of C4 or C6 fatty acids and optionally C2 fatty acids is beneficial for the following uses: (i) enhancing ketosis and / or (ii) preventing and / or treating resistance to the ketogenic diet in a subject following / adopting a ketogenic diet, wherein at least one of C4 or C6 fatty acids and optionally C2 fatty acids is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least one of C4 or C6 fatty acids and optionally C2 fatty acids is provided in a non-ketogenic amount by a dietary fiber blend contained in a non-ketogenic ketogenic diet-boosting agent composition. Optionally, the non-ketogenic ketogenic diet-boosting agent further comprises one or more of citric acid and / or nicotinamide riboside. It has been found that at least one of C4 or C6 fatty acids and optionally C2 fatty acids advantageously allows for a reduction in the amount of calories from the ketogenic diet, which the subject following / adopting the ketogenic diet needs to use to maintain and / or improve ketosis.
[0095] The inventors have found that when C4 and / or C6 fatty acids and optionally C2 are used and used in amounts that produce subphysiological plasma levels, ketone production in a ketogenic diet can be increased or enhanced, but are not themselves metabolic substrates or precursors for ketone body production. It has also been observed that C4 and C6 and optionally one or more of citric acid and / or nicotinamide riboside have a synergistic effect on ketosis.
[0096] definition
[0097] Throughout this application, the following terms and abbreviations may be used.
[0098] Fiber is an indigestible carbohydrate. Indigestible carbohydrates are carbohydrates that cannot be digested and absorbed in the human stomach and small intestine and enter the colon intact. Therefore, compounds like lactose, maltose, glucose, standard maltodextrin and standard starch are considered digestible. Fiber may or may not be fermented in the colon. The term "fermentable" refers to the ability to be broken down by microorganisms (anaerobic) into smaller molecules, particularly short-chain fatty acids and lactate, in the lower gastrointestinal tract (e.g., colon). Fermentability can be determined by the method described in Am.J.Clin.Nutr. [American Journal of Clinical Nutrition] 53, 1418-1424 (1991).
[0099] Butyrate dietary fiber is a fermentable dietary fiber. Butyrate dietary fiber or blends produce more caproate and butyrate than propionate and valerate SCFA. For the purpose of this specification, butyrate dietary fiber used in the present invention is defined as a dietary fiber or dietary fiber blend that is proven to produce butyrate and propionate in a beneficial ratio. The valeric acid and caproic acid produced by butyrate dietary fiber during fermentation are negligible.
[0100] The classic ketogenic diet contains a certain amount of lipids (by weight), whose weight is typically 4 times the total weight of protein and digestible carbohydrates. In the context of the present invention, the so-called ketogenic (weight) ratio is the weight ratio of the amount of lipids in the composition to the combined weight of protein and digestible carbohydrates. The ketogenic diet mentioned in the context of the present invention can be any type of ketogenic diet known in the art, preferably characterized in that the ketogenic weight ratio is between 1: 1 and 4: 1, that is, the ratio of the amount of fat to the combined amount of protein and digestible carbohydrates. Within the (sub) range of the above-mentioned ketogenic ratio of the present invention, the ketogenic dietary composition used in the context of the present invention preferably contains a lipid content that is at least twice the weight content of the carbohydrates. The ketogenic dietary composition as used in the context of the present invention, when followed, can induce a state of ketosis.
[0101] In alternative embodiments, the subject can take a dietary intervention that allows the ketosis of the subject to be induced by following an intermittent fasting scheme. The intermittent fasting (IF) used includes a diet or a feeding pattern, in which the food abstinence period that occurs regularly is longer than a typical overnight fast. Contrary to the traditional continuous energy restriction method, the IF program utilizes intermittent energy restriction, interspersing the less restricted or unrestricted feeding period with the period of severe energy intake restriction. Several forms of IF have been described, including time restricted feeding (TRF) (food intake is restricted to a specific time period of a day, usually between 8-12 hours per day), alternate day fasting (ADF) (alternating between no calories in one day and unlimited feeding on the second day), modified alternate day fasting (alternating between very few calories in one day and unlimited feeding on the second day) and regular fasting (fasting 1 or 2 days per week, and eating food arbitrarily 5 to 6 days per week).
[0102] As used herein, the term "ketosis" refers to a subject's blood ketone level above 0.5 mmol / L. Ketone levels maintained above 0.5 mmol / L and ideally in the range of 1 to 3 mmol / L have a therapeutic effect in humans [Anderson JC et al., Obes Sci Pract. 2021; 7(5): 646-656]. Blood ketone levels above 10 mmol / L are associated with signs of ketoacidosis. Although ketosis refers to a state of elevated ketones, ketoacidosis is a pathological and potentially life-threatening condition that can, in particular, lead to a decrease in blood pH and can induce coma.
[0103] In the context of the present invention, a "non-ketogenic ketogenic diet-boosting agent composition" is a composition or combination of compounds that does not increase or enhance ketone production by itself (i.e., it is a non-ketogenic composition), but can improve and / or enhance (enhance) the amount of ketone production induced by a ketogenic diet or a ketogenic intervention (such as an intermittent fasting period or carbohydrate restriction). Therefore, the composition is capable of increasing ("enhancing") the amount of ketone production in a subject on a ketogenic diet, and can maintain ketosis, and preferably is also capable of increasing the rate of ketone production, while not acting as or becoming a substrate for the production of ketone bodies. The increase in ketone body production induced by the non-ketogenic ketogenic diet-boosting agent composition in a subject who ingests a ketogenic diet or a ketogenic substrate is an increase in ketone body production relative to a subject who ingests the same amount of a ketogenic diet or a ketogenic substrate but without the "non-ketogenic ketogenic diet-boosting agent composition". Therefore, the non-ketogenic ketogenic diet-boosting agent composition itself is not a metabolic substrate for ketone body production (i.e., the composition is non-ketogenic), but is capable of increasing or enhancing ketone body production of a ketogenic composition or a ketogenic diet. Optionally, a compound in the composition may sometimes generate small amounts of ketone bodies that do not themselves increase plasma ketone concentrations and / or do not induce ketosis in the amounts provided, but are capable of stimulating ketone body formation in the ketogenic composition in a non-additive manner.
[0104] The non-ketogenic ketogenic diet-boosting agent composition also does not have a ketogenic ratio between 1: 1 and 4: 1. The non-ketogenic ketogenic diet-boosting agent composition can be incorporated into a ketogenic diet or can be a separate composition.
[0105] In alternative embodiments, a "non-ketogenic ketogenic diet-enhancer" is a composition or combination of compounds that does not itself increase or enhance the production of ketones so as to provide or maintain a state of ketosis (i.e., it is a non-ketogenic composition), i.e., does not serve as or become a substrate for the production of ketone bodies, or does not increase systemic and / or blood ketone body levels, at the specific dose provided. The composition improves / increases the amount of ketone production induced by a ketogenic intervention (such as an intermittent fasting period). The composition increases ("promotes") the amount of ketone production in a subject following an intermittent fasting regimen, and allows maintenance of ketosis and may also increase the rate of ketone production.
[0106] The expression "increases ketone body production" means that the amount of systemic and / or blood ketone bodies is higher in an individual on i) a ketogenic diet and ingesting (co-administering) ii) a non-ketogenic ketogenic diet-boosting composition according to the present invention, compared to an individual given the same (amount and type) of ketogenic diet but without the non-ketogenic ketogenic diet-boosting composition. In one aspect, the non-ketogenic ketogenic diet-boosting composition can reduce the time required to reach a therapeutically effective ketone concentration.
[0107] A non-ketogenic ketogenic diet-boosting agent composition that allows preventing the loss of ketone body production and maintaining ketosis in subjects on a long-term ketogenic diet, the non-ketogenic ketogenic diet-boosting agent composition preventing tolerance to the ketogenic diet, which is the loss of therapeutic efficacy over time. The non-ketogenic ketogenic diet-boosting agent composition according to the present invention does not cause ketoacidosis.
[0108] In the context of the present invention, a subject following or taking a ketogenic diet is a mammal, preferably a human. When referring to amounts per kilogram of body weight, this is the body weight of a subject following or taking a ketogenic diet and using a non-ketogenic ketogenic diet-boosting agent.
[0109] As used herein, the expression "non-ketogenic composition" refers to a composition that, when administered, does not itself lead to ketone body formation or does not increase the amount of systemic and / or blood ketone bodies, i.e., the non-ketogenic composition is not a metabolic substrate for the formation of ketone bodies, and / or it may optionally lead to the production of a small amount of ketone bodies (which itself cannot lead to ketosis), but it can stimulate ketone body formation in a non-additive manner in the presence of a ketogenic composition. Therefore, as used herein, a non-ketogenic amount refers to an amount of a certain compound, wherein this compound itself does not serve as a substrate for the formation of ketone bodies, or leads to the formation of no more than only a minimal amount of ketone bodies that cannot induce ketosis alone. Accordingly, in response thereto, the amount of systemic and / or blood ketone bodies will not increase.
[0110] In contrast, a ketogenic composition is a composition that can be used to promote the formation of ketone bodies and ketosis in a subject, wherein the composition itself comprises ketone bodies and / or substrates, which refer to precursors, usually in the form of fatty acids, for the formation of ketone bodies. A ketogenic diet is an exemplary ketogenic composition.
[0111] The non-ketogenic ketogenic diet-boost improved the amount of ketone production induced by the ketogenic diet, meaning it improved the production of the highest level of ketosis in subjects following the ketogenic diet.
[0112] As used herein, the term "maximum level of ketosis" indicates the maximum amount of blood ketones that can be achieved by a subject on a ketogenic diet, taking into account the maximum amount of ketones produced by hepatocytes when provided with a ketogenic fat blend. In the context of the present invention, an increase or enhancement of the maximum level of ketosis refers to the effect of the ketogenic booster composition as disclosed herein on the maximum amount of blood ketones relative to the maximum amount of blood ketones in a subject consuming a similar amount of a ketogenic diet without the use of a non-ketogenic ketogenic diet-boosting composition.
[0113] In the context of the present invention, resistance to a ketogenic diet means that a subject on a ketogenic diet suffers from resistance to the induction of ketosis, meaning that blood ketones remain or become too low for therapeutically effective ketosis, or meaning that despite following a KD, the subject experiences, for example, an increase in the frequency or severity of epileptic seizures.
[0114] The terms C2 fatty acids, C4 fatty acids and C6 fatty acids encompass any compound that is converted into acetic acid or acetate anion, butyric acid or butyrate anion and caproic acid or caproate anion (hexanoic acid or caproate) in the animal body, respectively. The terms derivatives of C2, C4 and C6 fatty acids contemplated herein include food-approved esters, complexes or salts of fatty acids. Derivatives of fatty acids according to the invention include (parts of) glycerol, physiologically acceptable complexes or salts thereof (e.g. calcium, potassium, sodium, magnesium, ammonium salts) and food-approved esters.
[0115] The term "fatty acyl chain" as used in the present invention refers to fatty acids linked by ester bonds.
[0116] As used herein, the term "supplement" or "dietary supplement" refers to a nutritional product that provides an individual with nutrients that the individual may not otherwise be able to conveniently consume in adequate amounts. Supplements typically provide selected nutrients but do not represent a major portion of the subject's overall nutritional requirements. Typically, they do not exceed 0.1%, 1%, 5%, 10% of the subject's daily energy requirements.
[0117] Glycerides are esters formed by glycerol and carboxylic acids, usually in the form of fatty acids. As an example, triglycerides (also known as triacylglycerols) are triesters derived from glycerol and three carboxylic acids. Under hydrolysis conditions (such as those during digestion), triglycerides can be used as a source of carboxylic acids or fatty acids. For example, each mole of tributyrin may be a source of three moles of butyric acid. Partial glycerides are esters formed by glycerol and fatty acids, wherein not all hydroxyl groups of glycerol are esterified; monobutyric acid glyceride and dibutyric acid glyceride are also sources of butyric acid according to the present invention, providing one mole and two moles of butyric acid per mole, respectively.
[0118] In the context of the present invention, when referring to the amounts of acetic acid, butyric acid or caproic acid, respectively, these amounts are calculated as their corresponding (molar) molecular quantities if different sources or derivatives are used.
[0119] In this document and its claims, the verb "comprise" and its conjugations are used in its non-restrictive sense, indicating that the part following the word is included, but parts not specifically mentioned are not excluded. "Essentially composed of..." means that the non-ketogenic ketogenic diet-boosting agent composition contains active ingredients and possible additional compounds, provided that these additional compounds have no substantial effect on the basic characteristics of the composition. In addition, referring to an element by the indefinite article "a" or "an" does not exclude the possibility of more than one element, unless the context clearly requires the presence of one and only one element. Therefore, the indefinite article "a" or "an" usually means "at least one". When % is mentioned in this article, wt% is meant unless otherwise specified.
[0120] Therapeutic ketosis
[0121] Thus, one aspect of the disclosure is a non-ketogenic ketogenic diet-boosting composition comprising at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid and (ii) optionally one or more citric acid and / or nicotinamide riboside, the composition comprising a combination of amounts effective to improve or maintain ketosis in a subject on a ketogenic diet in treating or preventing or ameliorating the symptoms of at least one disorder selected from the group consisting of:
[0122] i) Neurological diseases, including epilepsy, stroke, traumatic brain injury, and migraine;
[0123] ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and age-related mild cognitive impairment (MCI);
[0124] iii) neuromuscular disease, including amyotrophic lateral sclerosis, muscle deactivation, muscle atrophy and sarcopenia caused by aging, or risk of or frailty in old age;
[0125] iv) psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder;
[0126] v) metabolic diseases, including overweight and obesity (i.e., subjects with a BMI above 25 and 30, respectively), insulin resistance, type 1 and type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage disease, and mitochondrial disease;
[0127] vi) tumor diseases;
[0128] vii) Cardiovascular disease leading to heart failure.
[0129] In one aspect of the invention, the non-ketogenic ketogenic diet-boosting agent composition can increase ketone production and reduce the time required to reach therapeutically effective ketone concentrations. Reducing the time required to reach a ketotic state is particularly useful for refractory status epilepticus.
[0130] In another aspect of the present invention, the non-ketogenic ketogenic diet-boosting agent composition can also reduce the amount of fat in the ketogenic diet required to achieve and / or maintain a state of ketosis. In one embodiment, the amount of fat in the ketogenic diet can be reduced by about 10% while maintaining the total amount of calories in the ketogenic diet, provided that the ketogenic ratio is maintained within the level of 1:1 and 4:1. By reducing the amount of fat in the ketogenic diet, the ketogenic ratio will also be reduced by about 10%. It is believed that reducing the amount of fat in the ketogenic diet can make the diet easier to follow, that is, it improves patient compliance.
[0131] The subject is preferably a human subject in therapeutic need of ketosis.
[0132] Non-therapeutic ketosis
[0133] In another aspect of the invention, a non-therapeutic method is provided for (i) enhancing ketosis and / or (ii) preventing / treating resistance in healthy subjects on a ketogenic diet, the method comprising administering to the subject at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid, wherein at least one of the C4 or C6 fatty acid and optionally a C2 fatty acid is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least one of the C4 or C6 fatty acid and optionally a C2 fatty acid is provided in a non-ketogenic amount by a fiber blend in a non-ketogenic ketogenic diet-boosting agent composition. The non-ketogenic ketogenic diet-boosting agent composition can be administered as a separate composition or included in a ketogenic diet composition. In a specific aspect, a healthy subject (e.g., an athlete) is on a ketogenic diet for cosmetic weight loss or post-exercise muscle recovery.
[0134] In the context of a non-therapeutic approach, healthy subjects adopting a ketogenic diet for cosmetic weight loss preferably have a body mass index (BMI) between 25 and 18, more preferably between 25 and 20.
[0135] Ingredients of Non-Keto Ketogenic Diet-Booster Compositions
[0136] fatty acid
[0137] Preferably, the non-ketogenic ketogenic diet-booster composition comprises lipids, which include one or more fatty acids with six or less carbon atoms. Fatty acids according to the present invention that are not attached to other molecules are referred to as free fatty acids (FFA). In a preferred embodiment, the fatty acids used in the composition of the present invention are unbranched, more preferably unbranched and have an even number of carbon atoms. Most preferably, the non-ketogenic ketogenic diet-booster composition of the present invention includes fatty acids containing two carbon atoms (acetic acid and / or acetate) and / or four carbon atoms (butyric acid and / or butyrate) and / or six carbon atoms (hexanoic acid and / or hexanoate). The non-ketogenic ketogenic diet-booster composition preferably includes at least one of C4 or C6 fatty acids or derivatives thereof, preferably at least C4 fatty acids and optionally C2 fatty acids. In a preferred embodiment, it is preferred that at least C4 fatty acids, preferably C4 and C6 fatty acids, are present. Preferably, the non-ketogenic ketogenic diet-booster composition does not include C8 or higher fatty acids.
[0138] These fatty acids can be present in the first composition as such in the form of free fatty acids or as lipids comprising these fatty acids, preferably as lipids. In the context of the present invention, when referring to the amount of fatty acids, if different sources or derivatives are used, these amounts are calculated by the (weight) amount of the corresponding said fatty acids.
[0139] The lipids comprising fatty acids, as preferably used in the present invention, are preferably selected from the group consisting of triglycerides, diglycerides, monoglycerides, glycolipids, phospholipids and lysophospholipids. In one embodiment, the composition of the present invention comprises triglycerides containing fatty acyl chains and / or phospholipids containing fatty acyl chains, more preferably triglycerides containing fatty acyl chains. The glycerides of the present invention preferably have at least one, more preferably at least two, even more preferably 3 fatty acyl chains.
[0140] Lipids with fatty acyl chains are degraded by lingual, gastric, duodenal (ie pancreatic) and small intestinal lipases. Thus, administration of lipids containing fatty acyl chains results in the release of fatty acids in the stomach, duodenum, jejunum and ileum.
[0141] The preferred source of the lipid containing fatty acyl chain is by chemical synthesis. The source of these lipids can be one or more in animal, plant, fermentation, microalgae, GMO, non-GMO or its mixture. The alternative is the lipid obtained from the milk of non-human mammals, preferably cow's milk, goat's milk, sheep's milk, horse's milk, buffalo's milk, yak's milk, reindeer's milk, donkey's milk and camel's milk, particularly cow's milk and / or goat's milk. Milk lipid is also sometimes referred to as milk fat or butter fat. In a preferred embodiment, the lipid comprising short-chain fatty acyl chain is synthesized by glycerol and fatty acid by enzyme (e.g. esterase). Example is triacetin and tributyrin.
[0142] The non-ketogenic ketogenic diet-boosting agent composition preferably comprises at least one of a C4 or C6 fatty acid or a derivative thereof. In one embodiment, when a C2 fatty acid or a derivative thereof is additionally optionally present in the non-ketogenic ketogenic diet-boosting agent composition, the C2 fatty acid or a derivative thereof is present in a therapeutically effective dose to increase ketone production, maintain and / or improve ketosis in a subject on a ketogenic diet and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet.
[0143] The ketogenic diet referred to in the context of the present invention preferably has a ketogenic weight ratio between 1:1 and 4:1.
[0144] C2 fatty acids or derivatives thereof are optionally present in the non-ketogenic ketogenic diet-boosting agent composition in an amount to provide a daily dose of C2 fatty acids in the range of 0.5 mg to 30 mg per kg body weight per day, preferably 1.5 mg to 7.5 mg per kg body weight per day, more preferably 2.0 mg to 3.0 mg per kg body weight per day.
[0145] In one embodiment, C2 fatty acids are present in the non-ketogenic ketogenic diet-enhancer composition in the form of a triglyceride, triacetin or glyceroltriacetate. Triacetin, if present, is preferably present in the non-ketogenic ketogenic diet-enhancer composition in an amount to provide a daily dose of triacetin in the range of 0.6 mg to 36 mg per kg of body weight per day, preferably 3 mg to 9 mg per kg of body weight per day, more preferably 2.4 mg to 3.6 mg per kg of body weight per day.
[0146] In one embodiment, the non-ketogenic ketogenic diet-boosting agent composition comprises 0.2 mg to 4 g, more preferably 0.5 mg to 3 g, of C2 short-chain fatty acids or derivatives thereof per serving based on the dry weight of the composition.
[0147] In one embodiment, when a C4 fatty acid or a derivative thereof is present in the non-ketogenic ketogenic diet-boosting agent composition, the C4 fatty acid is present in a therapeutically effective dose to increase ketone production, maintain and / or improve ketosis in a subject on a ketogenic diet and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet. In a preferred embodiment, at least a C4 fatty acid and optionally a C2 fatty acid are preferably present.
[0148] C4 fatty acids are preferably present in the non-ketogenic ketogenic diet-boosting agent composition in an amount to provide a daily dose of C4 fatty acids in the range of 0.2 mg to 12 mg per kg body weight per day, preferably 1 mg to 6 mg per kg body weight per day, more preferably 1.5 mg to 3 mg per kg body weight per day.
[0149] In one embodiment, C4 fatty acids are present in the non-ketogenic ketogenic diet-boosting agent composition in the form of a triglyceride, tributyrin or glycerol tributyrate. Tributyrin, if present, is preferably present in the non-ketogenic ketogenic diet-boosting agent composition in an amount to provide a daily dose of tributyrin in the range of 0.2 mg to 14 mg per kg body weight per day, preferably 1 mg to 7 mg per kg body weight per day, more preferably 2 mg to 5 mg per kg body weight per day.
[0150] In one embodiment, the non-ketogenic ketogenic diet-boosting agent composition comprises 0.1 mg to 1.5 g, more preferably 0.2 mg to 1.2 g C4 short-chain fatty acids or derivatives thereof per serving based on the dry weight of the composition.
[0151] In one embodiment, when a C6 fatty acid is present in the non-ketogenic ketogenic diet-boosting composition, the C6 fatty acid is present in a therapeutically effective dose to increase ketone production, maintain and / or improve ketosis in a subject on a ketogenic diet, and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet.
[0152] C6 fatty acids are preferably present in the non-ketogenic ketogenic diet-boosting agent composition in an amount to provide a daily dose of C6 fatty acids in the range of 6 mg to 160 mg per kg body weight per day, preferably 30 mg to 85 mg per kg body weight per day, more preferably 50 mg to 70 mg per kg body weight per day.
[0153] In one embodiment, C6 fatty acids are present in the non-ketogenic ketogenic diet-boosting agent composition in the form of a triglyceride, trihexanoin or glycerol trihexanoate. Trihexanoin, if present, is preferably present in the non-ketogenic ketogenic diet-boosting agent composition in an amount to provide a daily dose of trihexanoin in the range of 5 mg to 185 mg per kg of body weight per day, preferably 35 mg to 90 mg per kg of body weight per day, more preferably 50 mg to 75 mg per kg of body weight per day.
[0154] In one embodiment, the non-ketogenic ketogenic diet-boosting composition comprises 2 mg to 20 g, more preferably 5 mg to 17 g, of C6 fatty acids or derivatives thereof per serving based on the dry weight of the composition.
[0155] Dietary fiber as a source of fatty acids
[0156] In an alternative embodiment of the invention, the fatty acid source is dietary fiber, wherein C2, C4 and / or C6 fatty acids are provided by microbial fermentation of these dietary fibers in the colon. In one embodiment, dietary fiber is provided in a non-ketogenic ketogenic diet-boosting agent composition in an amount sufficient to provide C2, C4 and / or C6 fatty acids within a therapeutically effective range according to the invention to increase ketone production in a subject on a ketogenic diet, maintain and / or improve ketosis and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet.
[0157] In a preferred embodiment, the dietary fiber in the non-ketogenic ketogenic diet-enhancer composition serves as a substrate for producing fatty acids. In the context of the present invention, the dietary fiber that serves as a substrate for fatty acids is a butyrate dietary fiber or a butyrate dietary fiber blend. The butyrate dietary fiber or blend produces more caproate and butyrate than propionate and valerate FA when fermented. For the purposes of this specification, since the production of valerate and caproate is negligible in any case, the butyrate dietary fiber used in the present invention is defined as a dietary fiber or a dietary fiber blend that can produce butyrate and propionate in a beneficial ratio. As used herein, the beneficial weight ratio of butyrate to propionate is defined as butyrate is more than propionate, that is, the weight ratio of butyrate to propionate is at least 1, preferably at least 1.1.
[0158] A butyrate-producing dietary fiber that can serve as a substrate for producing fatty acids, preferably producing acetate, butyrate, propionate and caproate, more preferably producing propionate and butyrate in a beneficial ratio, thereby being able to increase ketone production in a subject on a ketogenic diet, maintain and / or improve ketosis and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet.
[0159] As used herein, the expression "beneficial butyrate to propionate ratio" means that the weight of butyrate produced by fermentation of a fiber or fiber mixture is at least equal to or greater than the amount of propionate produced by fermentation. For example, locust bean gum or yeast beta-glucan produce more propionate than butyrate when fermented, and thus these fibers have a butyrate to propionate ratio below 1 and do not enhance or increase ketone production. In contrast, soy fiber and inulin are exemplary fibers that have a beneficial butyrate to propionate ratio when fermented.
[0160] In a preferred embodiment, the fermentation of butyrate-producing dietary fiber beneficially results in the production of fatty acids, wherein butyrate and propionate are produced in a weight ratio of butyrate: propionate of at least 1, preferably at least 1.1. The fermentation characteristics of dietary fiber and the accompanying butyrate to propionate ratio produced by a single source fiber or a fiber blend can be evaluated by fermentation assays known in the art. An exemplary method for evaluating fiber fermentation includes the use of an in vitro fermentation model using a pool of fecal samples from healthy adults exposed to about 10 mg / ml of fiber for 24 hours at 37°C under anaerobic conditions.
[0161] In one embodiment, 1 g to 2 g of dietary fiber is provided per 100 kcal total diet. In one embodiment, 25 g to 50 g of butyrate dietary fiber can be provided in a diet of about 2500 kcal per day, which can provide about 10 μM to about 250 μM of fatty acids, including C4 and C6 fatty acids, to the blood.
[0162] Dietary fibers that can provide C2, C4 and / or C6 fatty acids are fermentable dietary fibers, such as, for example, fermentable oligosaccharides and polysaccharides. Preferably, the dietary fiber is a butyrate dietary fiber with a beneficial fermentation profile, wherein butyrate and propionate are produced in a weight ratio of C4:C3 of at least 1, preferably at least 1.1. These fermentable fibers may include, but are not limited to, pectin, mucilage, gum, galacto-oligosaccharides, oligofructose, inulin, polyfructose, oligofructose, arabinogalactan, hemicellulose, resistant starch, soy fiber, oligosaccharides, or mixtures thereof.
[0163] In one embodiment, the butyrate-producing dietary fiber serving as a substrate for producing fatty acids is a fermentable fiber selected from the group consisting of pectin, mucilage, gum, galacto-oligosaccharide, oligofructose, inulin, polyfructose, oligofructose, arabinogalactan, (hemi)cellulose, resistant starch, soy fiber, oligosaccharides and mixtures thereof.
[0164] In certain embodiments, it is preferred to use a fiber blend. An exemplary fiber blend for use in the context of the present invention is a blend that is fermentable and provides a beneficial C4:C3 weight ratio of at least 1, preferably at least 1.1, even more preferably at least 1.5. An exemplary fiber blend is a fiber mixture comprising a) β-galacto-oligosaccharides, b) inulin, c) resistant starch and / or d) soluble soy polysaccharides, and provides fatty acids, particularly in a beneficial C4:C3 weight ratio.
[0165] Another exemplary fiber blend comprises a) FOS, b) inulin, c) soy fiber, d) resistant starch, e) gum arabic and / or f) cellulose. The blend is fermentable and provides fatty acids, particularly in a beneficial C4:C3 weight ratio of at least 1, preferably at least 1.1, even more preferably at least 1.5.
[0166] Another exemplary fiber blend comprises a) arabinoxylan, b) oat beta-glucan, c) pectin and / or d) resistant starch. The fiber mixture is fermentable and provides butyrate and propionate in a C4:C3 weight ratio of at least 1, preferably at least 1.1, even more preferably at least 1.5.
[0167] In one embodiment, therefore, there is provided a C2, C4 or C6 fatty acid or a derivative thereof, preferably at least one of a C4 and optionally also a C2 fatty acid, for use in the treatment of:
[0168] (i) Enhance ketosis and / or
[0169] (ii) preventing and / or treating resistance to a ketogenic diet, wherein at least one of C4 or C6 fatty acids and optionally C2 fatty acids is contained in the non-ketogenic ketogenic diet-boosting agent composition, or at least C4 or C6 fatty acids and optionally C2 fatty acids are provided in non-ketogenic amounts by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the non-ketogenic ketogenic diet-boosting agent composition, wherein fermentation of the butyrate-producing dietary fiber provides butyrate and propionate, and the weight ratio of butyrate:propionate is at least 1, preferably at least 1.1.
[0170] Optionally, the non-ketogenic ketogenic diet-enhancer may include one or more ingredients other than C4 or C6 fatty acids and optionally at least one of C2 fatty acids, such as optional additional ingredients selected from the group consisting of proteins, carbohydrates, vitamins, minerals, excipients, emulsifiers, stabilizers, and mixtures thereof. The final non-ketogenic ketogenic diet-enhancer composition is in the form of a ready-to-be-consumed liquid, or in the form of a powder reconstituted in water before use. Preferably, based on the weight of the non-ketogenic ketogenic diet-enhancer composition, protein accounts for less than 30%, more preferably less than 20%, and even more preferably less than 15% of the composition. Preferably, based on the weight of the non-ketogenic ketogenic diet-enhancer composition, if present, digestible carbohydrates account for less than 20%, more preferably less than 15%, and even more preferably less than 10% of the composition.
[0171] In another preferred embodiment, the non-ketogenic ketogenic diet-boosting agent composition comprises C6 fatty acids. In a preferred embodiment, both C4 and C6 fatty acids are included in the non-ketogenic ketogenic diet-boosting agent composition.
[0172] Thus, in one embodiment, at least one of C4 or C6 fatty acids (preferably C4 and C6 fatty acids) and optionally C2 fatty acids is provided for use in the following therapeutic applications: in a subject following / adopting a ketogenic diet
[0173] (i) Enhance ketosis and / or
[0174] (ii) preventing and / or treating resistance to a ketogenic diet, wherein at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is provided in a non-ketogenic amount by a butyrate dietary fiber or a butyrate dietary fiber blend contained in a non-ketogenic ketogenic diet-boosting agent composition.
[0175] Citric Acid
[0176] In another embodiment, the non-ketogenic ketogenic diet-boosting agent composition may further comprise citric acid. Citric acid is converted to isocitrate in the first step of the Krebs cycle (also known as the citric acid or TCA cycle). The citric acid used in the non-ketogenic ketogenic diet-boosting agent composition is preferably in the form of a potassium (K + ), sodium (Na + ), magnesium (Mg + ) or calcium (Ca 2+ In the context of the present invention, these amounts are calculated based on the (weight) amount of the corresponding citrate salt.
[0177] In one embodiment, therefore, at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is provided for use in a subject following / adopting a ketogenic diet.
[0178] (i) Enhance ketosis and / or
[0179] (ii) preventing and / or treating resistance to a ketogenic diet, wherein at least one of C4 or C6 fatty acids and optionally C2 fatty acids is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least one of C4 or C6 fatty acids and optionally C2 fatty acids is provided in a non-ketogenic amount by a dietary fiber blend contained in a non-ketogenic ketogenic diet-boosting agent composition, wherein the non-ketogenic ketogenic diet-boosting agent composition optionally further comprises citrate.
[0180] In one embodiment, when citrate is present in the non-ketogenic ketogenic diet-boosting agent composition, the citrate is present in a therapeutically effective dose to increase ketone production, maintain and / or improve ketosis in a subject on a ketogenic diet, and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet.
[0181] Citrate, if present, is preferably present in the non-ketogenic ketogenic diet-boosting agent composition in an amount to provide a daily dose of citrate in the range of 0.01 g to 0.4 g per kg body weight per day, preferably 0.04 g to 0.15 g per kg body weight per day, more preferably 0.08 g to 0.1 g per kg body weight per day.
[0182] Less than 15 g / day of K+ / Na+ / Mg+-citrate and possibly less than 20 g / day of Ca 2+ - Daily intake of citrate is considered safe and does not pose a risk of electrolyte imbalance.
[0183] In one embodiment, the non-ketogenic ketogenic diet-boosting composition comprises 5 mg to 20 g, more preferably 10 mg to 15 g, of citrate per serving based on the dry weight of the composition.
[0184] In one embodiment, the non-ketogenic ketogenic diet-boosting composition comprises C4 fatty acids, C6 fatty acids, and citrate.
[0185] Nicotinamide riboside
[0186] The present disclosure provides a non-ketogenic ketogenic diet-boosting agent composition, which further comprises an NAD+ precursor selected from the group consisting of tryptophan, nicotinic acid (nicotinic acid (niacin)), nicotinamide (nicotinamide or niacinamide (NAM)), nicotinic acid riboside (NaR), nicotinamide riboside (NR) and mixtures thereof. In a preferred aspect, the non-ketogenic ketogenic diet-boosting agent composition may comprise nicotinic acid, nicotinamide riboside and / or nicotinamide, preferably nicotinamide riboside and / or nicotinamide, more preferably nicotinamide riboside (NR). In the context of the present invention, these amounts are calculated according to the (weight) amount of the corresponding nicotinamide riboside. Throughout this application, equal amounts of nicotinamide calculated based on the weight of NR are foreseen.
[0187] As used herein, "nicotinamide riboside" includes derivatives thereof, such as L-valine ester and L-phenylalanine ester of nicotinamide riboside.
[0188] In one embodiment, therefore, at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid is provided for use in a subject following / adopting a ketogenic diet.
[0189] (i) Enhance ketosis and / or
[0190] (ii) preventing and / or treating resistance to a ketogenic diet, wherein at least one of C4 or C6 fatty acids and C2 fatty acids is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least one of C4 or C6 fatty acids and optionally C2 fatty acids is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in a non-ketogenic ketogenic diet-boosting agent composition, wherein the non-ketogenic ketogenic diet-boosting agent composition optionally further comprises an NAD+ precursor selected from niacin, nicotinamide riboside and / or nicotinamide, preferably nicotinamide riboside and / or nicotinamide.
[0191] In one embodiment, when nicotinamide riboside or nicotinamide is present in the non-ketogenic ketogenic diet-boosting agent composition, the nicotinamide riboside or nicotinamide is present in a therapeutically effective dose to increase ketone production, maintain and / or improve ketosis in a subject on a ketogenic diet and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet.
[0192] Nicotinamide riboside, if present, is preferably present in the non-ketogenic ketogenic diet-boosting composition in an amount to provide a daily dose of nicotinamide riboside in the range of 0.6 mg to 14.5 mg per kg body weight per day, preferably 1.4 mg to 4.5 mg per kg body weight per day, more preferably 2.5 mg to 3.5 mg per kg body weight per day.
[0193] In one embodiment, the non-ketogenic ketogenic diet-boosting composition comprises 0.2 mg to 2 g, more preferably 0.5 mg to 1.5 g nicotinamide riboside per serving based on the dry weight of the composition.
[0194] In one embodiment, the non-ketogenic ketogenic diet-boosting composition comprises C4 fatty acids, C6 fatty acids, citrate, and NAD+ precursors.
[0195] Non-ketogenic ketogenic diet-boosting agent composition administration form
[0196] The non-ketogenic ketogenic diet-boosting agent composition of the present invention can be in any form suitable for enteral, oral or parenteral administration. Non-limiting examples of parenteral administration include intravenous, intramuscular, intraperitoneal, subcutaneous, intraarticular, intrasynovial, intraocular, intrathecal, topical and inhalation.
[0197] In one aspect of the present invention, the composition according to the present invention may be used as a medicament comprising one or more pharmaceutically acceptable carrier materials.
[0198] In a preferred aspect, the composition according to the invention can be used as a nutritional product, for example as a nutritional supplement, for example as an additive to a ketogenic diet, as a enhancer, as a supplement in addition to a ketogenic diet.
[0199] The supplement (preferably for enteral application) can be a solid or liquid galenic formulation. Examples of solid galenic formulations are tablets, capsules (e.g., hard or soft shell gelatin capsules), pills, sachets, powders, granules, etc., which contain active ingredients and conventional galenic carriers. Any conventional carrier material can be utilized. The carrier material can be an organic or inorganic inert carrier material suitable for oral administration. The carrier material can account for up to 25wt% of the supplement, preferably up to 20wt%, more preferably up to 10wt%. In addition, additives such as flavoring agents, preservatives, stabilizers, emulsifiers, buffers, etc. can be added according to the conventional practices of nutrition and pharmaceutical preparation.
[0200] The composition according to the invention may also be used as a nutritional product for use in conjunction with tube feeding, for example as an additive to tube feeding, for intermittent or continuous administration.
[0201] The non-ketogenic ketogenic diet-booster composition may comprise a daily dose of one or more dosage units. The dosage unit may be in liquid form or in solid form, wherein in the latter case, the daily dose may be provided by one or more solid dosage units, for example in one or more capsules or tablets. The booster composition may be administered simultaneously with the ketogenic diet or separately or continuously at a time interval.
[0202] In one embodiment, the administration of the non-ketogenic ketogenic diet-boosting agent composition is at least monthly, preferably at least weekly, preferably at least daily; for example, the subject may receive one dose (or serving) or multiple doses (or servings) per day, preferably 1 to 6 times per day, more preferably 3 to 4 times per day. In some embodiments, the administration will continue for the rest of the individual's life. In specific embodiments, administration occurs until a detectable improvement in ketosis occurs, and in other cases, administration is continued to maintain the improved state.
[0203] One skilled in the art can determine the ideal duration for administering the composition.
[0204] In a specific non-limiting example, for a subject weighing 70 kg, consuming a 3000 kcal ketogenic diet per day with a ketogenic ratio of 1:1 to 4:1, the daily dose may be as follows:
[0205] C2 fatty acids or their derivatives (triacetin): (0.5 mg to 36 mg / kg / day)*70 kg = 35 mg / day to 2520 mg / day;
[0206] C4 fatty acids or their derivatives (tributyrin): (0.2 mg to 14 mg / kg / day)*70 kg = 7 mg / day to 980 mg / day;
[0207] C6 fatty acids or their derivatives (tricaproic acid glyceride): (6.5 mg to 185 mg / kg / day)*70 kg = 455 mg / day to 12.95 g / day;
[0208] Citric acid (0.01 g to 0.4 g / kg / day)*70 kg = 0.7 g / day to 28 g / day;
[0209] NR (0.6 mg to 14.5 mg / kg / day)*70 kg=42 mg / day to 1015 mg / day.
[0210] In another embodiment, a non-ketogenic ketogenic diet-boosting composition is provided consisting essentially of:
[0211] (i) 1 mg to 1.2 g C4 fatty acids / day; and optionally one or more of the following:
[0212] (ii) 32.5 mg to 17 g C6 fatty acids / day;
[0213] (iii) 0.05 g to 20 g citrate / day; or
[0214] (iv) 3 mg to 1.45 g nicotinamide riboside / day. These ranges refer to total amounts per 24 hours.
[0215] In another embodiment, a non-ketogenic ketogenic diet-boosting composition is provided consisting essentially of:
[0216] (i) 1 mg to 1.2 g C4 fatty acids / day; and optionally one or more of the following:
[0217] (ii) 32.5 mg to 17 g C6 fatty acids / day;
[0218] (iii) 0.05 g to 20 g citrate / day; or
[0219] (iv) 3 mg to 1.45 g nicotinamide riboside or an equivalent amount of nicotinamide per day; or
[0220] (v) 2.5 mg to 3 g C2 fatty acids per day. These ranges refer to total amounts per 24 hours.
[0221] In another embodiment, a non-ketogenic ketogenic diet-boosting composition is provided consisting essentially of:
[0222] (i) 1 mg to 1.2 g C4 fatty acids per day; and
[0223] (ii) 32.5 mg to 17 g C6 fatty acids / day;
[0224] and optionally one or more of the following:
[0225] (iii) 0.05 g to 20 g citrate / day; or
[0226] (iv) 3 mg to 1.45 g nicotinamide riboside or an equivalent amount of nicotinamide per day. These ranges refer to total amounts per 24 hours.
[0227] In one embodiment, a non-ketogenic ketogenic diet-boosting composition is provided, wherein each serving, based on dry weight of the composition, consists essentially of:
[0228] (i) 0.2 mg to 1.2 g C4 fatty acids;
[0229] (ii) 5 mg to 17 g of C6 fatty acids;
[0230] (iii) 10 mg to 20 g of citrate; and
[0231] (iv) 0.5 mg to 1.5 g nicotinamide riboside. Equal amounts of nicotinamide calculated based on the weight of NR are envisioned as nicotinamide riboside.
[0232] In another embodiment, a non-ketogenic ketogenic diet-boosting composition is provided consisting essentially of:
[0233] (i) 0.2 mg to 1.2 g C4 fatty acids;
[0234] (ii) 5 mg to 17 g of C6 fatty acids;
[0235] (iii) 10 mg to 20 g of citrate;
[0236] (iv) 0.5 mg to 1.5 g nicotinamide riboside, further optionally comprising
[0237] (v) 0 to 3 g C2 fatty acids, preferably 0.5 mg to 3 g C2 fatty acids.
[0238] In one embodiment, a non-ketogenic ketogenic diet-boosting composition is provided, intended for administration 4 to 6 times per day, each serving of which consists essentially of
[0239] (i) 0.1–0.3 mg C4 fatty acids;
[0240] (ii) 4.6–5.4 mg C6 fatty acids;
[0241] (iii) 9-11 mg citrate; and
[0242] (iv) 0.4-0.6 mg nicotinamide riboside.
[0243] In further embodiments, a non-ketogenic ketogenic diet-boosting composition is provided, intended for once daily administration, each serving of which consists essentially of
[0244] (i) about 1.2 g of C4 fatty acids;
[0245] (ii) about 17 g of C6 fatty acids;
[0246] (iii) about 20 g of citrate;
[0247] (iv) about 1.5 g nicotinamide riboside. Optionally, the non-ketogenic ketogenic diet-boosting composition intended for once daily administration further comprises (v) about 3 g C2 fatty acids.
[0248] The non-ketogenic ketogenic diet-boosting agent composition is formulated as a dietary supplement for a ketogenic diet. Typically, a serving of the non-ketogenic ketogenic diet-boosting agent composition is between about 10 g and 25 g.
[0249] The present invention further relates to a non-ketogenic ketogenic diet-boosting agent composition consisting essentially of:
[0250] (i) 4 mg to 480 mg C4 fatty acids;
[0251] (ii) 260 mg to 3.3 g C6 fatty acids;
[0252] (iii) 0.2 mg to 4.4 g citrate; and
[0253] (iv) 12 mg to 286 mg nicotinamide riboside,
[0254] (v) 20 mg to 1.2 g C2 fatty acids;
[0255] wherein the weight ratio of C2 and C4 fatty acids:C6 fatty acids is between 1:1.8 and 1:2.1, preferably between 1:1.9 and 1:2.0, based on dry weight;
[0256] The weight ratio of C2 and C4 fatty acids:citrate is between 1:2.4 and 1:2.7, preferably between 1:2.5 and 1:2.6, and
[0257] The weight ratio of C2 and C4 fatty acids: nicotinamide riboside is between 1:0.15 and 1:0.19, preferably between 1:0.16 and 1:0.18, and wherein the total weight of the composition is between about 10-20 grams.
[0258] In addition, a kit is provided, comprising 1) a non-ketogenic ketogenic diet-boosting agent composition and 2) one or more nutritional products with a ketogenic ratio between 1:1 and 4:1. In another aspect, the present disclosure provides a kit suitable for administering a food composition to a subject in need of ketosis. The kit is also provided for (i) enhancing ketosis associated with a ketogenic diet and / or (ii) preventing and / or treating resistance to a ketogenic diet in a subject following a ketogenic diet.
[0259] Examples
[0260] For a more complete understanding of the present disclosure, reference is now made to the following examples in conjunction with the accompanying drawings.
[0261] Example 1
[0262] An assay measuring ketone production in mouse hepatocytes (Hepa1-6 cell line) was used, wherein cells were first grown to a monolayer (growth phase), then exposed to starvation to deplete cellular lipid stores, followed by a ketogenic phase, wherein cells were cultured in the presence of oleic acid or a ketogenic dietary fat blend in the presence or absence of one of C2 fatty acids, C4 fatty acids, C6 fatty acids, citric acid, and nicotinamide riboside. Ketone body production was then determined by measuring β-hydroxybutyrate in the cell culture medium according to the details described below:
[0263] Growth phase: cells were grown at 90,700 cells / cm 2 The cells were seeded in 6-well plates at a concentration of 1:1 and grown for 24 h at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5 mM glucose, 10% fetal bovine serum (FBS), 4 mM L-glutamine, 1 mM pyruvate, and antibiotics (1% penicillin and streptomycin).
[0264] Starvation phase: At the end of the growth phase, the cells form a monolayer. The medium is changed to DMEM containing 1 mM glucose and antibiotics (1% penicillin and streptomycin) but without FBS. The medium is further supplemented with L-carnitine (a cofactor required for the uptake of fatty acids by mitochondria, where they are converted into ketones). The cells are incubated in this medium for 24 hours. During this time, the cells are extremely deprived of glucose, lipids and hormones contained in FBS, forcing them to consume and empty their lipid stores. Thus, any interference with nutrient assays is avoided. In addition, the starvation phase is believed to induce specific metabolic changes that maximize ketone production.
[0265] Ketogenic phase: At the end of the starvation phase, the medium was changed to Krebs-Henseleit buffer (KHB) supplemented with L-carnitine and test nutrients (Table 1, combinations of single fatty acids C2, C4, C6 and citrate, nicotinamide riboside and oleic fatty acid blends).
[0266] The fatty acid blend had a fatty acid composition similar to that used in the ketogenic diet (K-one). The content of each fatty acid in the blend is given as a molar ratio to oleic acid (OA), where the molar content of oleic acid is set to 1. Table 1 shows the concentration of each fatty acid in a 100 μM blend. Dilutions of this blend were used to determine Figure 1B and Figure 1D Dose response curve in . C2 and C4 were not included in this blend.
[0267] Table 1 Composition of fatty acid blends.
[0268]
[0269]
[0270] KHB is composed of salt and bicarbonate, as a chemical buffer, osmotic pressure and acidity (pH) are maintained at physiological levels. Before measuring, medium and long chain fatty acids are coupled to bovine serum albumin to make them soluble in KHB and allow them to be effectively taken up by these cells. This coupling is physiological, because in the human body, medium and long chain fatty acids are usually coupled to albumin, so as to transport in the blood circulation. Short chain fatty acids (C2, C4) are not coupled to albumin in this assay, because they are water-soluble and can circulate freely in the human body. These cells are incubated at 37 ° C for 6 hours. During this period of time, they produce ketones by test nutrients, and other nutrients are almost not disturbed by this, and secrete β-hydroxybutyric acid (β-Hb) into the culture medium.
[0271] β-Hb measurement: At the end of the ketogenic phase, the entire culture medium was collected and dried by vacuum centrifugation at 21°C for 20 hours. The dried pellet was resuspended in a small amount of assay buffer to produce a β-Hb concentration 10-20 times higher than the culture medium. These samples were deproteinized using spin columns to measure the free unbound fraction of β-Hb. The β-Hb concentration was then measured by an enzymatic reaction that produced a fluorescent product (Cayman Chemicals 700740). Fluorescence was measured on a fluorescence microplate reader and was directly proportional to the β-Hb concentration in the sample (ranging from 0.1 μM to 50 μM β-Hb).
[0272] 1.1 Effect of C2 on Ketone Production
[0273] When C2 was provided to hepatocytes alone at concentrations of 1 μM, 5 μM, and 10 μM, almost no bHB was produced. Figure 1A and Figure 1B When hepatocytes were incubated with a range of concentrations of OA, a dose-response curve for this long-chain fatty acid showed that the highest level of ketone production by incubation with OA alone was achieved at a concentration of 100 μM OA ( Figure 1C ). During ketogenic diet treatment, plasma concentrations of fatty acids in humans are typically above 100 μM. Therefore, to evaluate the ketogenic enhancing effects of C2, OA was assayed at a concentration of 100 μM. Combining 1 μM, 5 μM, or 10 μM C2 with 100 μM OA produced more βHb than 100 μM OA alone. The effects of the combination of C2 and OA on βHb production were non-additive, which could not be explained by the sum of the effects of C2 and OA on βHb production. Therefore, at physiological concentrations of 1 μM to 10 μM, C2 enhances ketone production at the highest levels of a single fatty acid.
[0274] The same experiment was performed on a fatty acid blend consisting of medium-chain, long-chain, and very long-chain fatty acids included in the ketogenic diet (denoted as K-one). Table 1 shows the composition of this blend, excluding C2. When hepatocytes were incubated with a range of concentrations of this blend, the dose-response curve showed that βHb production was maximized at a total fatty acid concentration of 100 μM ( Figure 1D ).
[0275] Fatty acid concentrations in plasma of people on a ketogenic diet exceed 100 μM, which means that the highest level of ketone production is achieved. Therefore, to evaluate the ketogenic enhancing effect of C2, the fatty acid blend was tested at a concentration of 100 μM. Combining 1 μM or 10 μM C2 with 100 μM fatty acid blend produced slightly more βHb than using an equimolar concentration of the fatty acid blend alone ( Figure 1B The effects of the combination of C2 and the fatty acid blend on βHb production were non-additive, as C2 alone did not produce βHb ( Figure 1B ). Thus, within the physiological concentration range of 1 μM to 10 μM, C2 can enhance βHb production at the highest level of the fatty acid blend included in the ketogenic diet.
[0276] In conclusion, low physiological concentrations of C2 from 1 μM to 10 μM can enhance the Figure 1A ) and a blend of fatty acids included in the ketogenic diet (K-one) ( Figure 1B) of ketones (βHb). Because no ketones were produced when C2 was provided to hepatocytes alone, the effect of C2 could not be explained by its use as a substrate. In addition, both the single fatty acid (oleic acid) and the fat blend (K-one) were tested with C2 at a concentration of 100 μM, at which they both maximized ketone production on their own ( Figure 1C , Figure D). Thus, C2 itself does not serve as a substrate for ketone production, but rather increases the maximum level of ketone production from a single fatty acid or blend of fatty acids above that obtained in the absence of C2.
[0277] 1.2 Effect of C4 on Ketone Production
[0278] Exposure of hepatocytes to C4 alone at concentrations of 1 μM, 5 μM, and 10 μM produced almost no βHb ( Figure 2A and Figure 2B The highest level of ketone production in the assay incubated with OA alone was achieved at a concentration of 100 μM OA ( Figure 1C ). Since fatty acid plasma concentrations are usually above 100 μM in humans on a ketogenic diet, OA was measured at a concentration of 100 μM. 1 μM, 5 μM, or 10 μM C4 combined with 100 μM OA produced more βHb than 100 μM OA alone ( Figure 2A ). In addition, βHb production increased with increasing concentrations of C4 provided. The effects of the combination of C4 and OA on βHb production were non-additive and could not be explained by the sum of the effects of C4 and OA on βHb production. Thus, administration of C4 in the physiological concentration range of 1 μM to 10 μM enhanced ketone production at the highest level of a single fatty acid.
[0279] Next, the ketogenic enhancement effect of C4 on ketone production in a fatty acid blend included in a ketogenic diet (K-one) was evaluated. The fatty acid blend did not contain C4. 10 μM C4 combined with 100 μM fatty acid blend produced more βHb ( Figure 2B The increase in βHb production achieved by combining 10 μM C4 and 100 μM fatty acid blend was non-additive, as C4 alone did not produce βHb ( Figure 2B ).
[0280] Hepatocytes were also incubated with C4 at a fixed concentration of 10 μM and a fatty acid blend ranging from 1 μM to 100 μM contained in a ketogenic diet (K-one). Control hepatocytes were exposed to the same concentration range of this fatty acid blend without C4. As the concentration of the fatty acid blend approached 100 μM, C4 gradually enhanced the ketone production of the fatty acid blend ( Figure 2C). These results demonstrate that low physiological concentrations of C4 can enhance βHb production from the blend of fatty acids included in the ketogenic diet.
[0281] To evaluate whether C4 can be used as a substrate for ketone synthesis at concentrations of 10 μM and lower, a dose-response curve of C4 as a substrate for βHb production was obtained, covering a C4 concentration range from 1 μM to 100 μM. The dose-response curve showed that when the concentration exceeded 10 μM, C4 began to be converted into βHb ( Figure 2D ). This further confirms that at concentrations below 10 μM, C4 can act as a functional enhancer of ketone production from a single fatty acid or a fat blend, and not as a direct substrate for ketone synthesis.
[0282] In general, C4 was found to enhance the activity of a single fatty acid (oleic acid, OA) at low physiological concentrations ranging from 1 μM to 10 μM. Figure 2A ) and a blend of fatty acids included in the ketogenic diet (K-one) ( Figure 2B ) of ketones (βHb). The effect of C4 on total ketone production was significantly greater than the sum of the contributions of equimolar concentrations of C4 and the fat blend. Therefore, this is non-additive and cannot be explained by C4 being used as a substrate for ketone production in the concentration range of 1 μM to 10 μM. This is also supported by the dose-response curve for C4, which shows that at concentrations above 10 μM, C4 begins to be efficiently converted to ketones ( Figure 2D ). Thus, C4 in the low physiological concentration range of 1 μM to 10 μM can enhance the maximum level of ketone production from a single fatty acid or a blend of fatty acids.
[0283] 1.3 Effect of C6 on Ketone Production
[0284] The study found that C6 at low physiological concentrations ranging from 1 μM to 10 μM enhanced the expression of a single fatty acid (oleic acid, OA) ( Figure 3A ) and a blend of fatty acids included in the ketogenic diet (K-one) ( Figure 3B and Figure 3C ) of ketones (βHb). The effect of C6 on total ketone production from the fat blend was significantly greater than the sum of the contributions of equimolar concentrations of C6 and the fat blend to total ketone production. Therefore, this is non-additive, so this cannot be explained by C6 being used as a substrate for ketone production in the concentration range of 1 μM to 10 μM. This is also supported by the dose-response curve for C6, which shows that at concentrations above 10 μM, C6 begins to be efficiently converted to ketones ( Figure 3D). Therefore, the data indicate that C6 functionally upregulates ketone production over a concentration range of 1 μM to 10 μM. Both the single fatty acid (oleic acid) and the K-one fat blend were tested at a concentration of 100 μM, at which they both maximized ketone production on their own ( Figure 1C and Figure 1D ). The K-one fat blend contains trace amounts of C6 (Table 1). However, the C6 concentration in the 100 μM K-one blend is 20 to 200 times lower than the C6 concentration range that can enhance ketogenesis of the blend (1 μM to 10 μM). Although the trace amounts of C6 in the K-one fat blend may have already stimulated ketogenesis, our data show that the addition of C6 in a concentration range of 1 μM to 10 μM can further enhance the highest level of ketone production of the fatty acid blend. In summary, at low physiological concentrations between 1 μM and 10 μM, C6 can functionally enhance ketone production of a single fatty acid or a blend of fatty acids.
[0285] 1.4 Effect of citrate on ketone production
[0286] In similar experiments as detailed above for C2 and C4, citrate in the range of physiological to supraphysiological concentrations from 200 μM to 1000 μM was found to increase the fatty acid blend (K-one) contained in the ketogenic diet ( Figure 4A-4C ) of ketone (βHb) production. The K-one fat blend contained no citrate (Table 1). This fat blend was tested at a concentration of 100 μM, at which it achieved the highest level of ketone production on its own ( Figure 1D The effect of citrate on the total ketone production of the fat blend was significantly greater than the sum of the ketone production achieved by the same (equimolar) amount of citrate or the fat blend alone ( Figure 4A and Figure 4B In fact, citrate alone did not produce ketones, but when added to the fat blend, it increased the ketone production of the fat blend by about 10%-20% ( Figure 4A-4C ; Figure 4C Shown is the condition of 200 μM citrate Figure 4A and Figure 4B Mean values of experiments shown, *P<0.05). Thus, citrate enhances ketone production at the highest level of the fatty acid blend included in the ketogenic diet.
[0287] 1.5 Effects of Nicotinamide Riboside on Ketone Production
[0288] Treatment with a ketogenic diet results in a massive depletion of NAD+ and other metabolically relevant NAD+ derivatives such as NADP+, thereby creating a state of NAD+ depletion. Therefore, it was hypothesized that nicotinamide riboside (NR) could replenish NAD+ and thus maintain ketone production in hepatocytes more efficiently than other NAD+ precursors, including nicotinamide (NAM), niacin (NA), nicotinic acid (defined as the combination of NA and NAM), or the amino acid tryptophan (Trp). While NA and NAM are commonly referred to as vitamin B3, NR is a recently discovered naturally occurring member of vitamin B3. An assay was developed to measure the replenishment of NAD+ by NAD+ precursors to NAD+-depleted mouse hepatocytes (Hepa1-6 cells) under ketogenic-like dietary conditions. In this assay, mouse hepatocytes were deprived of glucose and depleted of NAD+ by incubation in a medium with very low glucose content (1 mM) (without vitamin B3, tryptophan (Trp), and FBS, and supplemented with 10 nM of an NAD+-depleting drug called FK866). Thereafter, the cells were given NR or NAM or niacin (a combination of NAM and NA at a 1:1 molar ratio) or Trp to replenish NAD+. At the end of this replenishment period, the cells were scraped and assayed using the EnzyChrom TM Extraction was performed using NAD+ extraction buffer in the NAD / NADH assay kit. The NAD+ content of these cells was determined using the same kit following the manufacturer's manual. The NAD+ measurement is based on a lactate dehydrogenase reaction in which NAD+ is reduced to NADH, which in turn reduces the Formazan (MTT) reagent. The intensity of the color of the reduction product measured at 565nm is proportional to the NAD+ concentration in the sample. The assay is highly specific for NAD+ and is minimally interfered with by NADP+ or NADPH (<1%).
[0289] The study found that FK866 treatment significantly depleted NAD+ in hepatocytes, with the consumption being approximately 70% of the baseline NAD+ content of untreated hepatocytes ( Figure 5A , P<0.0001). In addition, the study found that providing NR could dose-dependently replenish NAD+ levels to this baseline level or above within 24 hours of treatment ( Figure 5A ). In addition, the study found that at a high concentration of 1mM, NR can increase the NAD+ content in NAD+-depleted hepatocytes, and its increase is significantly greater than that of an equimolar amount of NAM or niacin ( Figure 5A ), and at lower concentrations below 150 μM, the increase was greater than that of equimolar amounts of niacin ( Figure 5C These differences were not due to changes in cell viability, as cell counts (determined by ATP content measurements) were equal between treatments ( Figure 5B ). Thus, in NAD+-depleted mouse hepatocytes, NR was more effective than NAM and niacin in replenishing NAD+.
[0290] To measure the effect of supplementing NAD+ in hepatocytes with NR on ketone production, mouse hepatocytes were nutrient deprived in a medium containing low (1 mM) glucose, but the medium did not contain fetal bovine serum, vitamin B3 (niacin, NA, NAM) or NAD+ precursors in the form of Trp, but supplemented with L-carnitine. The cells were simultaneously treated with FK866. These conditions produced ketogenic diet-like nutritional conditions and depleted the cells of NAD+. After 18 hours of incubation, FK866 was removed from the medium and a range of NR concentrations were added to supplement NAD+. After 24 hours, the cells were switched to Krebs-Henseleit buffer (KHB) containing L-carnitine and a range of oleic acid (a long-chain fatty acid) concentrations (1 μM to 100 μM) for 6 hours to induce and measure the production and secretion of b-hydroxybutyrate (βHB) into the medium.
[0291] The study found that supplementation of NAD+-depleted hepatocytes with NR at concentrations of 10 μM, 150 μM, and 1000 μM increased ketone production at the highest level under nutritional conditions similar to a ketogenic diet ( Fig. 6A and Figure 6C ) and its NAD+ content ( Figure 6B ). Combined with the greater ability to replenish NAD+ levels (Figure 5), it is concluded that NR can sustain ketone production more effectively than NAM or niacin or Trp.
[0292] 1.6 Effect of the combination of C4 and C6 on ketone production
[0293] The study found that when similar experiments were performed on these single ingredients, a combination of C4 and C6 at low physiological amounts (5 μM each) was used to treat the ketogenic diet (K-one) ( Fig. 7A ) was enhanced in a non-additive manner. In the absence of a ketogenic fat blend, providing C4 or C6 alone or in combination produced almost no ketones, but when the combination of C4 and C6 was added to the fat blend, ketone production from the fat blend increased by about 40%. The observed increase was higher than would be predicted based on the effects of C4 and C6 on ketone production alone ( Fig. 7A The 3rd and 4th bars are compared to the 6th bar, respectively). The dotted line represents the threshold of ketone production induced by the ketogenic fat blend. Figure 7BThe synergistic effect between the ketogenic fat blend and the combination of C4 and C6 is shown; the middle bar shows the expected effect on ketone production by adding the observed effects of C4 and C6 on ketone production individually, and the third bar on the right shows the actual synergistic effect observed for the co-incubation of C4 and C6. In summary, C4 and C6 together synergistically promote the highest level of ketone production of the ketogenic fat blend.
[0294] 1.7. Effects of the combination of C4, C6, citrate, and NR or NAM on ketone production
[0295] In the next assay, the potentiating or enhancing effects of 5 μM C4, 5 μM C6, 200 μM citrate with 10 μM NR or 10 μM NAM were evaluated.
[0296] The experimental setup was similar to that of the single component experiments described above, except that the medium used in the starvation phase was modified:
[0297] At the end of the growth phase, the cells formed a monolayer and the medium was changed to DMEM containing 1 mM glucose and antibiotics (1% penicillin and streptomycin) but without FBS. The medium was further supplemented with L-carnitine (a cofactor required for the uptake of fatty acids by mitochondria, where they are converted to ketones). In order to specifically evaluate the effects of NR or NAM in the combination of various components, the medium was also depleted of vitamin B3 and tryptophan, since tryptophan can compensate for the lack of B3 (NAD+ precursor).
[0298] At the end of the starvation period, the medium was changed to Krebs-Henseleit buffer (KHB) supplemented with L-carnitine and the test nutrients used were as follows:
[0299] i) Complete combination of C4, C6, citrate and NR
[0300] ii) Complete combination of C4, C6, citrate and NAM
[0301] iii) Ketogenic Fat Blend
[0302] iv) Complete combination of C4, C6, Citrate and NR with ketogenic fat blend
[0303] v) Complete combination of C4, C6, Citrate and NAM with ketogenic fat blend
[0304] The production of βHB was then evaluated as described above. It was found that in the absence of a ketogenic fat blend, neither the combination with NR nor the combination with NAM produced significant amounts of ketones ( Figure 8). The use of the ketogenic fat blend alone results in ketone production, which is reflected by the dotted line in the figure and is referred to herein as the threshold level for ketone production. The combination with NR or the combination with NAM is further added to the ketogenic fat blend, resulting in a significant increase in ketone production, exceeding the threshold level. Unexpectedly, in both combinations, the increase above the threshold level brought about by either combination is greater than the ketone production achieved by either combination alone in the absence of the ketogenic fat blend. Therefore, the results demonstrate that the combination with NR and the combination with NAM have a non-additive synergistic effect on the ketone production of the ketogenic fat blend. Therefore, it was found that the combination of C4, C6, citrate with NR or NAM can enhance the highest level of ketone production in the ketogenic fat blend.
[0305] 2. Evaluation of dietary fiber fermentation
[0306] The fermentation of dietary fiber was evaluated using a standard adult intestinal microbiota library. The library was established by donating feces from 6 healthy adult volunteers (Caucasians, aged 25-60 years old, no antibiotics used within 3 months before donation, self-assessed health status). Before starting fermentation with the test compound, the standardized adult feces library was incubated overnight (37 ° C; 300 rpm) in SIEM (standard ileal effluent medium) under anaerobic conditions to activate bacteria, see: Schuren F et al., The i-screen:AVersatile Preclinical Platform for Gut Microbiota Studies [i-screen: General preclinical platform for intestinal microbiota research]. J Prob Health. [Journal of Probiotics and Health] 7: 212, 2019.
[0307] Dietary fibers were tested at concentrations of 6-10 mg / ml, depending on their viscosity and / or fermentability. All fibers were tested in triplicate. The following conditions were used:
[0308] - Partially hydrolyzed guar gum (Benefibre and Optifibre) 6.6 mg / ml
[0309] -Inulin (Orafti HP) 10mg / ml
[0310] -GOS (Vivinal GOS) 6mg / ml
[0311] -Locust bean gum (LBG) 6mg / ml
[0312] -Soybean fiber (Fibrim) 10mg / ml
[0313] -Soybean fiber (Fuji) 10mg / ml
[0314] -Cellulose (Vitacel) 10mg / ml
[0315] - Yeast β-glucan (YBG) 10mg / ml
[0316] -Mixture A, containing GOS, inulin, soy fiber (Fuji), resistant starch (Novelose 330), 10 mg / ml
[0317] -Mixture B, containing FOS, inulin, soy fiber (Fibrim), resistant starch (Novelose 330), gum arabic, cellulose (Vitacel), 6.6 mg / ml
[0318] Each run included a negative control (blank control medium containing only that feces pool), and all conditions started at pH 6.3. After 24 h of anaerobic fermentation in SIEM medium at 37°C, samples were collected for pH measurement and metabolite analysis.
[0319] The pH values were measured by immersing a 423 pH-electrode (Mettler Toledo, Columbus, OH, USA) connected to a Handy-lab pH meter (Schott Glas, Mainz, Germany) directly into the sample.
[0320] SCFA (covering acetate, propionate and n-butyrate) and branched chain fatty acids (BCFA) (covering isobutyrate and isovalerate) were analyzed according to the method described by Jouany et al. (1982) and modifications described by Van Nuenen et al. (2003). Briefly, the fermented material in the i-screen sample was centrifuged (about 12,000g, 5min). Cells were removed from the supernatant by sterile filtration (0.45μm). A mixture of formic acid (20%), methanol and 2-ethylbutyric acid (internal standard, 2mg / ml in methanol) was added. 3μl of the sample was injected into a GC column (ZB5HTinferno, ID 0.52mm, film thickness 0.10μm; Zebron; Phenomenex, USA) in a Shimadzu GC-2014 gas chromatograph at a split ratio of 75.0.
[0321] The results showed that after 24 hours of fermentation, inulin, GOS, soy fiber, cellulose and the two mixtures obtained higher butyrate / propionate ratios (higher than 1 and >1.1) compared with the blank control ( Fig. 9). Dietary fibers having a butyrate to propionate ratio of at least 1 and mixtures of such fibers are considered to be butyrate-producing dietary fibers according to the present invention. In contrast, the butyrate / propionate ratios of partially hydrolyzed guar gum, LBG and YBG are still below 1.
Claims
1. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use in the treatment of: (i) enhance ketosis associated with a ketogenic diet and / or (ii) preventing and / or treating resistance to a ketogenic diet, Wherein at least one of C4 or C6 fatty acids and optionally C2 fatty acids is contained in the non-ketogenic ketogenic diet-boosting agent composition, or at least C4 or C6 fatty acids and optionally C2 fatty acids are provided in non-ketogenic amounts by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the non-ketogenic ketogenic diet-boosting agent composition.
2. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to claim 1, wherein enhancing ketosis means increasing the blood ketone concentration in a subject on a ketogenic diet using a non-ketogenic ketogenic diet-boosting composition compared to the blood ketone concentration in a subject consuming the same ketogenic diet without the use of a non-ketogenic ketogenic diet-boosting composition.
3. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to claims 1 and 2, wherein the non-ketogenic ketogenic diet-boosting composition further comprises one or more compounds selected from a) citric acid and / or b) nicotinamide riboside and / or nicotinamide.
4. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding claims, wherein the non-ketogenic ketogenic diet-boosting agent composition is in the form of a nutritional supplement.
5. At least one of the C4 or C6 fatty acids and optionally C2 fatty acids for use according to any of the preceding claims, wherein the at least C4 or C6 fatty acid and optionally the C2 fatty acid are provided in a non-ketogenic amount by a butyrate dietary fiber or a butyrate dietary fiber blend, and Wherein these dietary fibers are selected from pectin, glue, gum, galacto-oligosaccharide, oligofructose, inulin, polyfructose, oligofructose, arabinogalactan, hemicellulose, resistant starch, fuji soybean, oligosaccharide, or a mixture thereof, and Wherein these dietary fibers have a fermentation profile providing butyrate and propionate in a weight ratio of at least 1, preferably at least 1.
1.
6. C4 or C6 fatty acids and optionally at least one of their C2 fatty acids for use according to any of the preceding claims, wherein the amount of the C4 fatty acid is 0.2 to 12 mg per kg of body weight per day, and / or the amount of the C6 fatty acid is 5 to 185 mg per kg of body weight per day.
7. At least one of the C4 or C6 fatty acids and optionally C2 fatty acids for use according to any of the preceding claims, wherein the non-ketogenic ketogenic diet-boosting agent composition is administered one to six times a day, preferably three to four times a day, or continuously, or wherein the non-ketogenic ketogenic diet-boosting agent composition is administered continuously by tube.
8. At least one of the C4 or C6 fatty acids and optionally C2 fatty acids for use according to any one of the preceding claims, wherein the subject following a ketogenic diet suffers from a condition selected from the group consisting of: i) Neurological diseases, including epilepsy, stroke, traumatic brain injury, and migraine; ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and age-related mild cognitive impairment (MCI); iii) neuromuscular disease, including amyotrophic lateral sclerosis, muscle deactivation, muscle atrophy and sarcopenia caused by aging, or risk of or frailty in old age; iv) psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder; v) metabolic disorders, including insulin resistance, type 1 and type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases; vi) tumor diseases; vii) Cardiovascular disease leading to heart failure.
9. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any one of the preceding claims, wherein the subject following a ketogenic diet is a subject suffering from epilepsy.
10. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding claims, wherein a maximum level of ketosis is increased.
11. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use according to any of the preceding claims, wherein the non-ketogenic ketogenic diet-boosting agent composition comprises (i) C4 fatty acids (ii) C6 fatty acids (iii) citric acid, and (iv) nicotinamide riboside or nicotinamide, and optionally (v) C2 fatty acids.
12. At least one of the C4 or C6 fatty acids and optionally C2 fatty acids for use according to any of the preceding claims, wherein the non-ketogenic ketogenic diet-boosting agent composition is administered at a dose of (i) 0.2mg to 12mg C4 fatty acids per kg body weight per day (ii) 6.5mg to 163mg C6 fatty acids per kg body weight per day (iii) 0.011 g to 0.39 g citric acid per kg body weight per day, and (iv) 0.6 mg to 14.3 mg nicotinamide riboside or an equivalent range of nicotinamide per kg body weight per day, and optionally (v) 0.5 mg to 30 mg C2 fatty acids per kg body weight per day.
13. A non-therapeutic method for treating healthy subjects following a ketogenic diet (i) Enhance ketosis and / or (ii) Preventing resistance to the ketogenic diet The method comprises administering to the subject at least one of a C4 or C6 fatty acid and optionally a C2 fatty acid, wherein one of the C4 or C6 fatty acid and optionally a C2 fatty acid is contained in a non-ketogenic ketogenic diet-boosting agent composition, or at least the C2 or C4 fatty acid or a derivative thereof is provided in a non-ketogenic amount by a butyrate dietary fiber blend in the non-ketogenic ketogenic diet-boosting agent composition.
14. The non-therapeutic method according to claim 13, wherein the method is used to promote non-therapeutic weight loss and / or improve recovery after exercise, and wherein optionally, promoting non-therapeutic weight loss is performed in subjects with a BMI between 18 and 25, preferably between 20 and 25.
15. A non-ketogenic ketogenic diet-boosting agent composition consisting essentially of: (i) 0.2 mg to 1.2 g C4 fatty acids; (ii) 5 mg to 17 g of C6 fatty acids; (iii) 10 mg to 20 g of citrate; and (iv) 0.5 mg to 1.5 g nicotinamide riboside or nicotinamide, wherein these amounts are based on the dry weight of the composition, and wherein these amounts are on a per serving basis, and wherein optionally the composition is in the form of a supplement.
16. At least one of a C4 or C6 fatty acid and optionally a C2 fatty acid for use in the treatment of: (i) enhance ketosis associated with fasting or intermittent fasting, wherein at least one of the C4 or C6 fatty acids and optionally the C2 fatty acids is contained in the non-ketogenic ketogenic diet-boosting agent composition, or at least one of the C4 or C6 fatty acids and optionally the C2 fatty acids is provided in a non-ketogenic amount by a butyrate dietary fiber blend contained in the non-ketogenic ketogenic diet-boosting agent composition.
